|
Clinical study of CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid MalignanciesEntering the 21st century ,several tumor immunotherapy success in clinical trial make the immunotherapy very hot in research field. Especially after 2010, CAR-T cell immunotherapy have an amazing effect on B cell Malignant Tumors. What is CAR-T cell immunotherapy? T cells are collected from a patient,they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface.After this reengineering, the T cells are known as “chimeric antigen receptor (CAR) T cells.” CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells.The CAR T cells are then infused into the patient and they are the “attacker” cells that will recognize, and kill, cancerous cells that have the targeted antigen on their surface. Hebei Senlang Biotechnology Co., Ltd together Second Hospital of Hebei Medical University develop the CAR-T cell immunotherapy clinical study ,use the CD19 as target for CD19+ Patients With Relapsed or Refractory Blood Malignant Tumors ( main including ALL and B-cell Lymphoma) | ![]() Second Hospital of Hebei Medical University hematology department Director Luo jianmin 0311-66002304
Hebei Senlang Biotechnology Co., Ltd Ph.D. Li jianqiang 0311-88803029 |
ABOUT US
----------Senlang CAR-T----------
![]() 进步前辈手艺来历 森朗生物自立研发的“CAR-T细胞免疫医治恶性肿瘤新药”,已累计投入研发资金近1亿元,请求专利14项,受权发现专利2项、实......更多 | ![]() 资深研发专家 高等迷信家李建强博士一向努力于 肿瘤免疫医治的根本研讨、临床研 发和产物的临床转化......更多 | ![]() 权势巨子临床步队 以河北医科大学第二病院血液科罗 建民主任领衔的临床团队,在血液 病的诊断与医治方面有着......更多 | ![]() 保险保证权利 名目组为每名到场研讨的患者采办临 床实验义务保险,患者在限制地区范 围内到场该项研讨,产生超......更多 | ![]() 捐献手艺办事 本研讨中CAR-T细胞出产及医治 的相干用度由申办方承当,对您 收费。收费规模包含T......更多 |
| Room 512 and 513, Building 1, 136 Huanghe Avenue, Shijiazhuang High-tech Development Zone, Hebei Province,China Tel:+86-311-82970975、82970973 |